Metabolic bottleneck in single‑E3‑ligase‑dependent dogma and discovery of intractable targets A substantial proportion of endogenous oncogenic proteins that drive cancer cell proliferation and resistance lack drug‑binding pockets, rendering them intrinsically 'undruggable.' To overcome this limitation, the molecular glue degrader (MGD) modality, which forces the degradation of target proteins, has emerged as an innovative alternative. Existing clinical guidelines based on thalidomide derivatives rely exclusively on Cereblon (CRBN) as the E3 ubiquitin ligase carrier, creating a chronic blind spot. This extreme dependence on a single ligase impairs substrate diversity and tissue selectivity, and constitutes an engineering bottleneck that, upon chronic administration, triggers off‑target genotoxic noise and resistance mutations.

Hybrid multimodal omics‑AI structural dynamics platform: validation of non‑canonical neosubstrate complex docking To fundamentally eliminate the degradation constraints imposed by CRBN, this study deployed an integrated screening pipeline that combines chemoproteomics, ubiquitin‑remnant profiling, and generative AI‑driven protein structure modeling (e.g., AlphaFold 3). By performing real‑time computation on genomic and proteomic variance tensors, the team precisely mapped the landscape of >600 E3 ligases present in nature within an in‑silico space. This effort enabled the back‑calculation of allosteric interaction energies between newly identified E3 ligases and cancer‑cell‑specific neosubstrates that were absent from prior genetic maps, thereby providing the first demonstration of structural integrity in molecular docking for these complexes.

Degron mapping and CRISPR‑based functional screening to elucidate target‑protein degradation kinetics To validate the degradative efficacy of the identified ligase‑neosubstrate pairs, the investigators employed degron mapping together with CRISPR‑based functional genomics as complementary interfaces. Nanomechanical calculations of charge distribution and van der Waals forces within the interface topology induced by the molecular glue allowed quantification of the catalytic turnover constant governing the conjugation of target oncogenic proteins to poly‑ubiquitin chains. Using this approach, highly resistant malignant proteins such as acute myeloid leukemia (AML) drivers and solid‑tumor‑specific RNA‑binding protein 39 (RBM39) were successfully routed into the 26S proteasome degradation pathway, achieving precise “pin‑clamp” degradation.

Establishing programmable next‑generation MGD design standards and shifting oncology governance toward drug‑resistance mitigation The integrated systems‑biology and structure‑based pharmacology data dossier redefines cancer‑treatment standards from a post‑translational inhibition paradigm to a programmable protein‑degradation infrastructure that computationally corrects the three‑dimensional tensor of ligase‑neosubstrate conformational changes to eradicate targets at the source. By constructing a discovery pipeline that instantly swaps in alternative ligases via virtual simulation upon emergence of resistance mutations, a next‑generation, patient‑tailored MGD trench is established. The derived non‑canonical ligase binding free‑energy constants will serve as a computational backbone for pre‑emptively calculating CMC viability thresholds in global IND programs of multinational pharmaceutical companies, and will act as a master reference to dramatically compress regulatory approval timelines for next‑generation companion‑diagnostic (CDx)‑linked precision oncology therapeutics.